Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTFields + atezolizumab + docetaxel + nivolumab + pembrolizumab
- Development stage
- Unknown
- Lead developer
- NovoCure
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Transdermal, Intravenous
01
Overview
This combination involves **TTFields** (Tumor Treating Fields), a non-invasive, non-pharmacological therapy using low-intensity alternating electric fields to disrupt cancer cell division; **atezolizumab**, a monoclonal antibody targeting PD-L1; **docetaxel**, a chemotherapy agent; **nivolumab**, a monoclonal antibody targeting PD-1; and **pembrolizumab**, another monoclonal antibody targeting PD-1. This combination is not a standard treatment but represents a hypothetical or experimental approach combining immunotherapy, chemotherapy, and a non-pharmacological modality.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)SEPT2/6/7 (Septin 2/6/7 complex)TUBB (Tubulin (alpha and beta subunits))MicrotubuleCD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on TTFields + atezolizumab + docetaxel + nivolumab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTFields + atezolizumab + docetaxel + nivolumab + pembrolizumab.